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 Analogues of glucose-dependent insulinotropic polypeptide (GIP) with agonist or antagonist 
effects at the GIP receptor have been developed. 
 Studies in rodents have noted that both reduced and enhanced activity of GIP can prevent or 
reverse obese non-insulin dependent forms of diabetes.  
 Species differences in GIP receptor responsiveness have complicated the extrapolation of 
evidence from rodents to humans. 
 Clinical studies have shown the potential of GIP receptor agonists to be used in combination 













The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory 
polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial 
interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was 
reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition 
in non-diabetic individuals.  Also, attention was diverted away from GIP by the successful 
development of glucagon-like peptide-1 (GLP-1) receptor agonists, and a therapeutic strategy for GIP 
became uncertain when evidence emerged that both inhibition and enhancement of GIP action could 
prevent or reverse obese non-insulin dependent forms of diabetes in rodents.  Species differences in 
GIP receptor responsiveness complicated the extrapolation of evidence from rodents to humans, but 
initial clinical studies are investigating the effect of a GIP antagonist in non-diabetic individuals.   A 
therapeutic role for GIP agonists was reconsidered when clinical studies noted that the insulinotropic 
effect of GIP was increased if near-normal glycaemia was re-established, and GIP was found to have 
little effect on glucagon secretion or adipose deposition in obese type 2 diabetes patients.  This 
encouraged the development of designer peptides that act as GIP receptor agonists, including chimeric 
peptides that mimic the incretin partnership of GIP with GLP-1, where the two agents exert 
complementary and often additive effects to improve glycaemic control and facilitate weight loss.  
Polyagonist peptides that exert agonism at GIP, GLP-1 and glucagon receptors are also under 




After the discovery of gastric inhibitory polypeptide (glucose-dependent insulinotropic polypeptide; 
GIP) evidence soon emerged to show that this hormone contributed to more physiological effects than 
the inhibition of gastric acid secretion [1, 2].    Potentiation of nutrient-induced insulin release secured 
a place for GIP alongside glucagon-like peptide-1 (GLP-1) as an incretin hormone, and reports of a 
reduced incretin effect in type 2 diabetes mellitus raised the possibility that GIP might offer a 
therapeutic opportunity to restore the incretin effect [3-5]. Moreover, GIP enhanced first-phase 
glucose-induced insulin secretion in non-diabetic individuals and promoted proliferation of islet beta-
cells in rodent models and insulin-secreting cell lines [6].  However, the insulin-releasing effect of 
GIP was diminished in type 2 diabetes, whereas the insulin-releasing potency of GLP-1 was largely 
retained in type 2 diabetes, and GLP-1 additionally exerted a satiety effect and suppressed prandial 
glucagon secretion [7-9]. Also, meal-stimulated GIP concentrations were similar in people with and 
without type 2 diabetes, whereas GLP-1 concentrations were reduced in type 2 diabetes, providing an 










interest in a possible therapeutic role for GIP was over-shadowed by the development of GLP-1 
receptor agonists.  The therapeutic strategy for GIP also became undecided when inhibition of GIP 
action as well as administration of excess GIP were both shown to prevent or reverse obese non-
insulin dependent forms of diabetes in rodents [11].  However, recent clinical studies have identified 
potential benefits of GIP in combination with GLP-1, and this review examines the evidence and 
evaluates the opportunities for GIP-based therapies in the treatment of type 2 diabetes.   
Physiological studies in human obesity and type 2 diabetes 
An increased density of GIP-producing K-cells has been observed in the duodenum of type 2 diabetes 
patients, but this does not appear to significantly alter GIP responses to an oral glucose challenge [ 10, 
12 ].   A meta-analysis of 23 studies found generally similar peak GIP concentrations with only a 
marginally lower incremental area-under-the-curve of GIP concentrations in response to nutrient 
stimulation in subjects with type 2 diabetes compared to non-diabetic controls [ 10 ].  It is noted, 
however, that GIP secretion is highly sensitive to the types and amounts of nutrients ingested, 
previous diet and the rate of gastric emptying: thus each of these variables could obscure subtle 
alterations of GIP secretion in type 2 diabetes [13-16]. While the ability of GIP to enhance nutrient-
induced insulin release is reduced in type 2 diabetes, this is most evident in severely hyperglycaemic 
patients, suggesting that this probably reflects the impaired functional status of the beta-cells in these 
patients rather than a defect of GIP action [17, 18].  Also, the ability of GIP to enhance the acute (first 
phase) insulin response is better preserved in type 2 diabetes than the later (second phase) response.  
The therapeutic relevance of this is that loss of the first phase nutrient-induced insulin response is an 
early feature of defective beta-cell function in type 2 diabetes, and restoring the acute response is 
known to considerably improve prandial glycaemic control [19].    
Nutrient-stimulated GIP secretion in obese subjects is similar or higher than non-obese controls, but is 
often reduced with coexistent type 2 diabetes, although findings have not been consistent and appear 
to vary with the extent of hyperglycaemia and the time period studied after nutrient intake   [10, 16-
18, 20 ].  Nevertheless, a protracted reduction of calorie intake with weight loss is generally 
associated with increased meal-stimulated GIP secretion and an increased insulin response [20, 21].   
Evidence from bariatric procedures 
In obese non-diabetic individuals, gastric banding with reduced food intake has mostly decreased GIP 
concentrations, whereas vertical sleeve gastrectomy with rapid delivery of gastric content into the 
duodenum has generally raised acute GIP responses, although studies have not been consistent [ 22-
28].  Roux-en-Y gastric bypass (RYGB), which diverts food from a small gastric pouch into the 











concentrations, and no obvious correlation with the extent of improved glycaemic control has been 
identified amongst individuals with type 2 diabetes [25, 29-32].  Improved glycaemic control after 
RYGB has been attributed in large part to increased concentrations of GLP-1 and possibly peptide YY 
that result from rapid delivery of nutrients into the distal small intestine [ 33-35].  No relationship has 
been found between changes in glycaemic control and the reduction in GIP concentrations after 
surgical removal of the duodenum [36], and although hydrothermal ablation of the duodenal mucosa 
can reduce hyperglycaemia in type 2 diabetes this has not been compared with GIP concentrations 
[37].   Thus physiological and bariatric studies in humans have not identified a clear therapeutic 
strategy for GIP in the treatment of obesity or type 2 diabetes. 
Experimental studies 
Genetic obesity-diabetes syndromes in mice that are caused by defects of leptin production or action 
(notably ob/ob and db/db mutants) and diet-induced murine obesity and glucose intolerance are  
associated with hyperplasia of duodenal K-cells, increased GIP content of the duodenum and 
increased GIP concentrations [38, 39].  Interruption of GIP production by administration of GIP 
receptor antagonists, antibodies against GIP or against the GIP receptor can partially reduce or reverse 
the obesity, hyperglycaemia, hyperinsulinaemia and insulin resistance in these animal models, and 
reduce glucagon and corticosterone concentrations [40-45].  Also, GIP receptor knockout (Gipr(-/-)) 
prevented the development of diet-induced obesity in mice and reduced weight gain in ob/ob mice, 
consistent with the effect of GIP receptor antagonists  [46 ].  However, there are small differences in 
the amino acid sequences of human GIP compared with rat GIP and mouse GIP (Figure 1), and the 
human GIP receptor has only 81% homology with rat and mouse GIP receptors [47 ].  These 
structural differences are associated with important functional differences.  For example, whereas rat 
GIP receptor antagonists such as rat GIP(3-30) exert a strong competitive antagonist effect in rodents,  
human GIP(3-30) exerts little or no antagonism against the rat or mouse GIP receptor [ 48, 49 ].  
Moreover, human (Pro3)GIP acts as an antagonist at the rat and mouse GIP receptors  but acts as an 
agonist at the human GIP receptor [ 47-49].  Thus species differences of GIP receptor responsiveness 
to GIP antagonists make it difficult to extrapolate antagonist evidence from rodent models to man.   
Regarding surgical information between species, a RYGB procedure in diet-induced obese mice 
reduced the obesity and decreased GIP production by the Roux-limb, but not by the biliopancreatic 
limb of the intestine, and the serum GIP response was maintained  [50]. This supports the view that 
different GIP responses to feeding after RYGB in human subjects may reflect differences in the length 
of the Roux limb and the adaptations of the mucosa.   
Although the foregoing experimental evidence indicates that inactivation of GIP can reduce obesity 











models can also improve glycaemic control, mostly without a significant effect on body weight.  This 
is attributed to increased insulin secretion, increased β-cell mass and a reduced effect of C-terminally 
modified GIP on adipose deposition [51-54].  Moreover, transgenic mice that over-express GIP and 
show improved glycaemic control and increased β-cell function, also show reduced diet-induced 
obesity [55].  GIP has been variously reported to increase feeding or have no effect on feeding 
although intracerebroventricular administration of GIP decreased food intake and body weight in 
normal mice, possibly acting centrally by altering sensitivity to leptin [56-58]. Potent GIP receptor 
agonists also decreased food intake and body weight in diet-induced obese mice [ 58 ]. 
Early development of GIP analogues 
Although the clinical investigation of GIP analogues has lagged far behind that of GLP-1 analogues, 
early development proceeded largely in parallel. When studies in Coleraine led by Peter Flatt noted 
that the dipeptidyl peptidase-4 (DPP-4) degradation product GIP(3-42) was less potent than native 
GIP(1-42) and antagonised the effect of native GIP(1-42),  the group examined a series of N-
terminally modified GIP analogues and found that modifications at N1 or N2 generally conferred 
DPP-4 resistance and enhanced insulin releasing and anti-hyperglycaemic activity [59-62].   However, 
amino acid substitution at N3 reduced biological activity and antagonised the action of native GIP(1-
42) [11].  To increase the stability of GIP, D-Ala2 substitution, acylation and PEGylation were 
undertaken and the potential therapeutic application of these molecules was studied in rodent models 
[63-67].   
Because experimental studies in obese-diabetic rodents indicated that both increased and decreased 
activity of GIP receptors can improve glycaemic control with or without concurrent weight loss, it 
was uncertain which therapeutic strategy to adopt: GIP antagonism or agonism?  Moreover, 
differences in the activation and inhibition of GIP receptors between rodents and humans complicated 
the extrapolation of rodent studies into a clinical context [68, 69].  To address this,  detailed analyses 
of structure-activity relationships for native GIP and variant GIP molecules have been undertaken 
using an assay of cAMP production by Chinese hamster ovary (CHO) cells and monkey kidney 
(COS) cells transfected with cDNA to express human GIP receptors [70, 71].  These studies 
determined that the biological activity of GIP resides with the N-terminal 1-14 sequence of residues, 
while the middle region (residues 19-30) can improve binding affinity and C-terminal residues (31-
42) appear to contribute conformational advantage to the molecule [Figure 1].    
GIP antagonism 
Although the anti-obesity and anti-hyperglycaemic effects of GIP inhibition in rodents fuelled interest 











patients has yet to take place. In vitro studies established that truncations, deletions or substitutions 
along the 1-14 sequence of human GIP results in molecules with very weak partial agonism or no 
agonism, and some of these molecules have shown biological antagonism of human GIP receptor 
function.  GIP(3–30) and GIP(5–30) are reported to be the most potent competitive antagonists at 
human GIP receptors, and the antagonistic effect of GIP(3-30) is increased when competing against 
GIP molecules that lack a C-terminal region  [71].  Thus, although endogenous active circulating 
GIP(1-42) is degraded by DPP-4 to GIP(3-42), which has a competitive antagonist effect at the GIP 
receptor, the C-terminal residues of GIP may partially protect against this antagonism [71, 72].  GIP 
may also be degraded by neutral endopeptidases and several truncated GIP variants such as GIP(6–
30) and GIP(7–30) have been identified.  These act as GIP receptor antagonists in rodents, but have 
little effect at human GIP receptors [73-75].   A long-acting GIP antagonist [palmitoylated human 
GIP(3–30), with a C-terminal extension based on the GLP-1 receptor agonist exendin], promoted 
weight loss and improved glycaemic control in fat-fed mice [76].  However, an infusion of human 
GIP(3-30) in healthy non-diabetic subjects significantly reduced the insulin response and increased 
glucose excursions, confirming that inhibiting GIP action raises blood glucose in non-diabetic humans 
[77, 78].  The clinical effect of inhibiting GIP action with GIP(3-30) was compared to inhibiting GLP-
1 action with exendin(9-39), and it was concluded that GIP may normally provide a greater stimulus 
for insulin secretion than GLP-1 [78].  The effect of GIP receptor antagonism in human type 2 
diabetes remains to be established.  
GIP agonism 
Recent clinical interest in the potential therapeutic opportunities of GIP agonism was encouraged by 
evidence that the insulinotropic potency of GIP is increased when near-normal glycaemia is 
established in type 2 diabetes patients receiving insulin  [79-81]. Although this might reflect in part a 
sparing effect on the beta cells, the first phase glucose-induced insulin response is enhanced by GIP 
and glucagon secretion is only increased at low glucose concentrations, improving the 
counterregulatory response to hypoglycaemia [81 ]. The need to first re-establish near normal 
glycaemia points to the use of GIP in combination with another glucose-lowering agent:  indeed the 
effect of chronic administration of GIP alone or a potent GIP receptor agonist alone in obese type 2 
diabetes patients has not been established.   While GIP may increase adipose deposition in lean human 
subjects, partly due to increased vascular perfusion of adipose tissue, this effect appears to be 
diminished in non-diabetic obese individuals, suggesting that GIP does not promote adipose 
deposition in human obesity  [82, 83 ].  A further property ascribed to GIP is that of improved bone 
health through inhibition of bone resorption [84].  This is consistent with the decrease in bone mineral 
density, decreased bone strength, decreased cortical thickness and increased osteoclast activity in GIP 










The foregoing provides evidence to support the therapeutic value of GIP agonism in combination with 
at least one other glucose-lowering agent in the treatment of hyperglycaemia in humans.  But why 
should the diametrically opposite approaches of GIP agonism and GIP antagonism improve obesity-
diabetes status in rodent models?  Suggestions in the literature include the possibility that chronic 
exposure to GIP receptor agonists might cause desensitisation of the GIP receptor through receptor 
down-regulation which reduces the effect of GIP, and/or degradation products of GIP might 
antagonise receptor function [87].  Whether such ideas could be extrapolated to human type 2 diabetes 
remains a further conjecture, but it is suggested that if GIP antagonists can improve glucose 
homeostasis without enhancing insulin secretion, then other glucose-lowering mechanism must be 
taking place [41-43]. Possible effects on other aspects of metabolism, hunger-satiety behaviour and 
exercise remain to be clarified.    
GIP therapy in combination with GLP-1  
Many of the potential benefits of GIP administration are complementary to those of GLP-1, and use of 
the two hormones together could offer advantages for the treatment of obese type 2 diabetes.  Both 
hormones contribute to the incretin effect to enhance prandial insulin secretion, and they may act on 
the islet beta-cells in part through different and partially additive mechanisms [88].  Both can promote 
beta-cell mass in vitro and in animal models but this has yet to be clearly shown in type 2 diabetes 
patients.  The suppressive effect of GLP-1 on glucagon secretion should moderate a possible tendency 
for high GIP concentrations to increase glucagon secretion without hypoglycaemia, and the satiety 
and weight loss effects of GLP-1 should counter the possibility that GIP might increase adipose 
deposition as seen in lean individuals. Both hormones promote bone health and have been reported to 
confer benefits against age-related cognitive decline [89].  GLP-1 is already established as an 
effective therapy for obese type 2 diabetes and chimeric designer peptides provide a means to achieve 
agonism at both GLP-1 and GIP receptors with the same molecule [90-92].  
Studies in diet-induced obese and genetically obese diabetic rodents have noted that administration of 
GIP or GIP analogues with potent GIP receptor agonism can increase the weight-reducing, insulin-
releasing and blood glucose-lowering effects of GLP-1 [90-95].  Also, GLP-1 and GIP together 
increased energy expenditure and did not promote appetite in rodent models, while a study in 
overweight and obese non-diabetic subjects has indicated that GIP might reduce the satiety effect of 
GLP-1 [96].  Initial ‘proof of principle’ studies in non-diabetic and type 2 diabetic subjects using 
peptides with agonistic effects at GIP and GLP-1 receptors recorded similar or greater glucose-
lowering activity than equivalent doses of a GLP-1 receptor agonist alone [91, 92].   For example, a 
GIP/GLP-1 dual agonist with the catchy nickname ‘twincretin’, which incorporates substantial N-











produced a dose dependent decrease in HbA1c over 6 weeks in type 2 diabetes subjects (Figure 2) 
[91, 92, 97]. To protect against enzymatic degradation by DPP-4, the twincretin has aminoisobutyric 
acid at N2, and to further prolong the active form in the circulation there is a fatty acid link at the C-
terminus to attach to albumin.  Several other GIP/GLP-1 dual agonist peptides have now been 
reported, including the N-ac(d-Ala2)GIP/GLP-1-exe hybrid which has D-Ala at N2 to protect against 
DPP-4 degradation and C-terminal homology with exenatide [95].  This dual agonist has been shown 
to decrease HbA1c and body weight in high fat fed mice, and increase beta-cell mass, pancreatic 
insulin content and insulin responsiveness.     
The most extensively studied GIP/GLP-1 dual agonist is tirzepatide (LY3298176).  This 39 amino 
acid peptide is based on the biologically active N-terminal GIP(1-14) sequence with an N2 
aminoisobutyric acid substitution (Figure 2) [98].  The mid-sequence contains substitutions 
compatible with GLP-1 receptor agonism and there is a C20 fatty diacid chain linked via glutamic 
acid to the Lys20 residue to facilitate attachment to albumin to prolong viability in the circulation.  
There is also an amidated exenatide-like C-terminal sequence.  The structure confers stronger 
agonism for the GIP receptor than the GLP-1 receptor: binding affinity for the GIP receptor is similar 
to native GIP(1-42), but about 5-fold weaker for the GLP-1 receptor than native GLP-1.  This 
provides a degree of balance that takes account of the physiologically higher circulating 
concentrations of GIP than GLP-1.  The modifications that reduce enzymatic degradation provide 
sufficient durability for once-weekly subcutaneous administration.    Preclinical studies in rodent 
models indicated that the peptide could increase beta-cell function more than GIP agonism or GLP-1 
agonism alone, reduce food intake and body weight, and increase energy expenditure [98].   
The preclinical observations were confirmed in humans: initial 1-month trials with tirzepatide in 
healthy subjects and people with type 2 diabetes noted improved oral glucose tolerance, an increased 
insulin response to oral glucose and reduced body weight in a dose-dependent manner [98].  In a 
phase 2  double-blind placebo-controlled study, 316 type 2 diabetes patients treated by lifestyle + 
metformin  (baseline HbA1c 8.2%, body weight 92 kg and BMI 32 kg/m2) were randomised to once 
weekly subcutaneous injection of  tirzepatide  (1, 5, 10, and 15 mg), dulaglutide (1.5 mg) or placebo 
for 26 weeks [99].  Compared to placebo, tirzepatide was associated with dose related mean 
reductions in HbA1c of 1∙00%, 1∙67%, 1∙83% and 1∙89% for the 1,5,10 and 15mg doses respectively.  
Dulaglutide reduced HbA1c by 1∙21% in this study suggesting that high doses of tirzepatide exerted 
considerably greater glucose-lowering efficacy than the maximum dose of dulaglutide in routine 
clinical use.  Tirzepatide was also associated with a marked dose-dependent loss of body weight (by 
0∙9 kg with the 1 mg dose to 11∙3 kg with the 15 mg dose) versus reductions of 2∙7 kg for dulaglutide 











reduction in blood pressure were also noted with tirzepatide, and there was no change in the incidence 
of cardiovascular events or hypoglycaemia. 
Set against the efficacy of high doses of tirzepatide is a high incidence of gastrointestinal 
disturbances, although these were mostly early and transient. Also of note, over half of patients 
receiving the 15mg dose of tirzepatide developed antibodies to this agent, but these were generally of 
low titre and did not appear to compromise efficacy.    
Preliminary accounts of the effects of several other GIP/GLP-1 dual agonist peptides in healthy 
subjects and type 2 diabetes patients have been reported, eg once-daily injection of  RG7697 
(MAR709) and NNC0090-2746  [82-85, 103].  These accounts confirm that GIP receptor agonism 
does not interrupt the glucose-lowering or weight-lowering effects of GLP-1 receptor agonism, and 
may provide additional efficacy, but not with the same potency as the long-acting once-weekly agent 
tirzepatide.    
GIP as part of a triple agonist  
Triple agonist (triagonist) peptides with stimulatory effects at the glucagon, GLP-1 and GIP receptors 
(GcgR/GLP-1R/GIPR) have been developed with a balance of activation at the three receptors. Their 
structures are largely based on the amino acid sequence of glucagon with positional modifications, 
and their activity at each of the receptors has been assessed in vitro.  Each has shown strong glucose-
lowering and weight-lowering effects in rodents and/or monkeys [93, 97, 104, 105]. Examples of 
triagonists are shown in Figure 2. Weight-lowering was particularly effective with some triagonists 
which may be attributable to the inclusion of glucagon agonism: glucagon exerts a satiety effect and 
promotes energy expenditure.  It is anticipated that the glucose-lowering effects conferred by the 
GLP-1 and GIP components of the triagonists are more than compensating for the effect of glucagon 
receptor agonism to promote endogenous glucose production.   Triagonists can also reduce hepatic 
lipid stores in animal models: this favours use in the treatment of hepatic steatosis, noting that the 
removal of ectopic hepatic fat is a feature of the success of calorie restricted diets in the early 
treatment of obese type 2 diabetes [106].   
In principle, designer polyagonist molecules offer the opportunity to produce a variety of amino acid 
sequences with different activities at different receptors.  This could enable glucose-lowering and 
weight-lowering potencies to be selected to closely align with the therapeutic needs of the individual - 
a move towards precision medicine with a single molecule.  By simultaneously targeting multiple 
receptors it should be possible to achieve treatment goals with lower dose-equivalents than required if 
only one or two differently acting agents is used.  Also, lesser effects at several receptors should 










activation required to produce the therapeutic effects might lead to long-term desensitisation, or incur 
risk of anaphylactic reactions [107].  Production cost and maintaining the physico-chemical stability 
of large peptides in injection media can be a challenge, and a particular caution resides with the 
immunogenicity of non-native peptide sequences and the development of antibodies as already seen 
with tirzepatide [98, 99].    
Many gastro-intestinal peptides with different effects on glucose homeostasis could be considered for 
therapeutic use in the management of obesity and type 2 diabetes, as agonists and antagonists, with or 
without GIP (table 1).    Effects of mixtures, hybrids and chimeras exerting agonist effects of these 
peptides without affecting GIP receptors have received preliminary assessment in obese and diabetic 
animal models, and several have proceeded into clinical development [103].   Combined peptide-
steroid molecules have also been developed, and formulations for enteral as well as parenteral 
administration continue to receive attention.  With a view to the long-term future it is possible that 
glucose-responsive (so-called ‘smart’) formulations could be devised to release the active agent(s) 
within the body to coincide with changes in blood glucose [107].     
Conclusion  
Therapeutic aspirations for GIP receded into the shadow of its incretin partner GLP-1 after the 
insulinotropic potency of GIP was shown to be much reduced in type 2 diabetes.  It was also difficult 
to reconcile evidence that both an increase and a decrease in GIP action could prevent or reverse 
obese non-insulin dependent diabetes in rodents.  Clinical attention to the therapeutic potential of GIP 
was rekindled after studies identified species differences in GIP receptor responsiveness and noted 
that the insulinotropic potency of GIP returned in type 2 diabetes patients when near normal 
glycaemia was re-established.   The complementary effects of GIP and GLP-1 to enhance nutrient-
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Legend to Figures 
Figure 1.   
Amino acid sequence of glucose-dependent insulinotropic peptide (gastric inhibitory peptide, 
GIP) showing functional properties and species differences.  Structure-activity relationships of 
variant GIP molecules were assessed using an assay of cAMP production by Chinese hamster ovary 
(CHO) cells and monkey kidney (COS) cells transfected to express human GIP receptors [70, 71].   
GIP(1-42) is the main active form of GIP, and GIP(1-30) is also active in the circulation.  The N-
terminal GIP(1-14) amino acids are essential for biological activity: the middle region (amino acids 
19-30) affect receptor binding affinity and C-terminal amino acids (31-42) provide conformational 
advantage.  GIP(1-42) is degraded by dipeptidyl peptidase-4 (DPP-4) to GIP(3-42), which can act as a 
competitive antagonist to GIP(1-42) at the GIP receptor.  GIP variants with further deletions at the N-
terminus can also act as antagonists at the GIP receptor: the antagonistic potency reduces with the 
number of deletions from the N-terminal sequence. The C-terminal region of GIP(1-42) reduces the 
competitive potency of GIP antagonists.  There are small variations in the amino acid sequences of 
human, rat and mouse GIP molecules which do not alter the essential active N-terminal region but can 














Amino acid sequences of glucose-dependent insulinotropic peptide (gastric inhibitory peptide, 
GIP), glucagon-like peptide-1 and glucagon compared with a dual GIP/GLP-1 receptor agonists 
and triple GIP/GLP-1/glucagon receptor agonists.  Amino acids consistent with GIP are shown in 
black.   X, aminoisobutyric acid.  A, D-Ala2.    a  GIP/GLP-1 ‘twincretin’ described by Finan et al 
[91].  b GIP/GLP-1 hybrid described by Pathak et al [95]. c GIP/GLP-1dual agonist tirzepatide also 
known as LY3298176 described by Coskun et al [98].   d  Triagonist A decribed by Finan et al [93].  e  













Table 1.  
Glucoregulatory effects of gastro-intestinal and pancreatic peptides in clinical use or being 
investigated as templates to develop GIP-based therapeutic interventions for obese type 2 
diabetes.  Based on a recent review [107].  ↑, increase; ↓, decrease; ↔, no clear change; ?, uncertain; 
*, depends on pathophysiological circumstances; CCK, cholecystokinin; GIP, glucose-dependent 
insulinotropic peptide; GLP1, glucagon-like peptide 1; Oxynto, oxyntomodulin; PYY, peptide 
tyrosine tyrosine; 
 HbA1c     Wt Food 
intake 




GIP ↓ ↑ ? ↓ ↑ ↑ 
GLP-1 ↓ ↓ ↓ ? ↑ ↓ 
Glucagon ↑ ↓ ↓ ↑ ↑ ↔ 
Insulin ↓ ↑ ↓ ↓↔↑* ↔ ↓ 
PYY ↔ ↓ ↓ ? ?  ↔↓ 
Oxynto ↓ ↓ ↓ ↑ ↑ ?  
Gastrin ↔ ↔ ↓ ↔ ↑ ?  
CCK ↔ ↔ ↓ ↔ ↔ ↔ 
Xenin ↔ ↓ ↓ ? ↑ ? 
 
Jo
ur
na
l P
re
-p
ro
of
